Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Palonosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 10/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | HRH1 | P35367 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 1/20 | 1.00 |
| ▸ | KCNQ1 | P51787 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Palonosetron SCHEMBL29402278 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL2989775 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7782594 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL7277880 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL10066801 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3748 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL13240607 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL4052980 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3747 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C | |
| Palonosetron SCHEMBL3746 | 1.00 | HTR3A (1.00) | HTR3AHTR3BADRA2AKCNE1ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940366-B9 | SOFT CAPSULES COMPRISING PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2009-12-02 | — | — | EP | claimed |
| EP-1940366-B1 | SOFT CAPSULES COMPRISING PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2009-04-08 | — | — | EP | claimed |
| US-5202333-A | Tricyclic 5-HT3 receptor antagonists | SYNTEX (U.S.A.) INC. (US) | 1993-04-13 | — | — | US | claimed |
| US-20170035748-A1 | DOSAGE FORMS OF PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20170035748-A1 | DOSAGE FORMS OF PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | HELSINN HEALTHCARE SA (CH) | 2017-02-09 | — | — | US | disclosed |
| US-20110213150-A1 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-01 | — | — | US | disclosed |
| US-20110213150-A1 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-09-01 | — | — | US | disclosed |
| WO-2010056656-A2 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-20 | — | — | WO | disclosed |
| US-20080152704-A1 | Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability | HELSINN HEALTHCARE S.A. (CH) | 2008-06-26 | — | — | US | disclosed |
| US-20080152704-A1 | Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability | HELSINN HEALTHCARE S.A. (CH) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213150-A1 | PREPARATION OF CRYSTALLINE PALONOSETRON HYDROCHLORIDE | HTR3A, HTR5A, HTR3C | HTR3A 1/4885HTR3B 13/4885ADRA2A 90/4885 |
| US-20080152704-A1 | Dosage Forms of Palonosetron Hydrochloride Having Improved Stability and Bioavailability | MC2R, LPXN, CYP3A43 | HTR3A 20/4885HTR3B 98/4885ADRA2A 154/4885 |
| US-20170035748-A1 | DOSAGE FORMS OF PALONOSETRON HYDROCHLORIDE HAVING IMPROVED STABILITY AND BIOAVAILABILITY | MC2R, LPXN, CYP3A43 | HTR3A 20/4885HTR3B 98/4885ADRA2A 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.